Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XMT-1536 in Solid Tumors (Ovarian and NSCLC)
NCT03319628Phase 2Active, not recruiting
- Sponsor
- Mersana Therapeutics
- Start
- Dec 2017
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of upifitamab rilsodotin in ovarian cancer, non-small cell lung cancer (NSCLC), sponsored by Mersana Therapeutics. Started Dec 2017; status: active, not recruiting.
02
Drugs
upifitamab rilsodotin
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03319628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319628.